Physician profile
Rabinder Bhatti
NPI 1275709818
$6,287.97
in general payments reported to CMS, 2019-2025
26 companies · $652 in 2025
The $652 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,784 · 2020: $729 · 2021: $923 · 2022: $904 · 2023: $1,085 · 2024: $211 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,948.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $2,177.41 | 2019-2020 | |
| Boston Scientific Corporation | $1,893.22 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept, Infinion 16 |
| Medtronic, INC. | $521.51 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $257.96 | 2019-2022 | |
| Abbott Laboratories | $219.62 | 2019-2025 | Eterna, Proclaim |
| Scilex Pharmaceuticals INC. | $204.68 | 2019-2023 | Ztlido |
| Vertos Medical, INC. | $142.19 | 2021 | |
| Collegium Pharmaceutical, INC. | $126.30 | 2022-2023 | Xtampza, Belbuca |
| Relievant Medsystems, INC. | $106.52 | 2022 | |
| Spr Therapeutics, INC | $94.47 | 2025 | Sprint Pns System |
| Abbvie INC. | $82.08 | 2021-2023 | Botox |
| Protega Pharmaceutials INC | $80.98 | 2023-2025 | Roxybond |
| West Therapeutics Development, LLC | $52.37 | 2020-2021 | |
| Stryker Corporation | $49.45 | 2019 | |
| Pfizer INC. | $44.15 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $35.43 | 2020-2021 | |
| Bioventus LLC | $29.43 | 2019-2020 | |
| Depuy Synthes Sales INC. | $26.38 | 2021 | |
| Nalu Medical, INC. | $26.35 | 2025 | Nalu Neurostimulation System |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Forte Bio-Pharma LLC | $18.55 | 2023 | Prolate, Nalocet |
| Fidia Pharma USA INC. | $18.30 | 2019 | |
| United Orthopedics LLC | $17.06 | 2025 | |
| Grt US Holding, INC. | $15.50 | 2021 | |
| Painteq LLC | $13.71 | 2021 | |
| Allergan, INC. | $13.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rabinder Bhatti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.